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Abstract
Effectiveness of a treatment for neurocardiogenic syncope can be defined in terms of symptom 
response, quality-of-life, healthcare utilization, treatment side effects and cost-effectiveness. 
Most trials have focused on syncope recurrence or burden, without assessing quality-of-life 
formally. Drug and device interventions are characterized by a dearth of randomized controlled 
trials, with those few of robust design demonstrating little impact on recurrence of syncope. 
General advice includes hydration, trigger recognition and counter pressure maneuvers to  
attenuate episodes. Lifestyle recommendations have limited comparative effectiveness evidence, but  
are favored due to lack of side effects and low cost. The frequency of syncope improves in many 
patients regardless of the intervention, although ultimate recurrence of syncope remains high.
In the minority of patients seeking treatment due to recurrence, midodrine has reasonable sup-
porting evidence for effectiveness with some evidence for beta-blockers in older age patients. 
Emerging evidence favors pacing in patients with asystole during spontaneous (as opposed to 
provoked) syncope. Combining long-term implantable cardiac monitoring, tilt and adenosine 
triphosphate testing may yet accurately define the optimal minority who benefit from pacing. 
In the remaining majority, pharmacologic and device interventions should be used sparingly 
until clear benefits are established. Better understanding of patient fears, beliefs and behaviors 
may help develop cognitive therapies and improve quality-of-life alongside the focus on physical 
symptoms. (Cardiol J 2014; 21, 6: 616–624)
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Introduction
The question of how to approach therapy for 
neurocardiogenic syncope (NCS) does not come 
with a simple answer. In effect, a subgroup of pa-
tients with NCS seek help from their physicians 
for a recurrent, troubling and, at times, life-altering 
condition that many patients either minimize or 
even fail to report. In so doing, they declare them-
selves as treatment seeking, fundamental to the 
journey to clinical improvement regardless of the 
intervention. Along come physiologists who seek 
to understand dynamic alterations in blood pres-
sure regulation and cerebral perfusion, and who 
propose deductive interventions that “should help” 
because of presumed knowledge of the underlying 
mechanism of the faint. Thus, doctors prescribe 
thoughtful therapies, patients want to get better, 
and syncope generally improves or resolves.
This apparently effective empiric approach 
collides with systematic comparative effectiveness 
research methodology, which shows that most 
patients get better (i.e. syncope does not recur) 
regardless of intervention, including placebo, with 
trends to small incremental improvement with 
a small proportion of the many proposed agents or 
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interventions [1–3]. This chapter addresses the 
issue about whether or not any treatment for NCS 
really is effective.
Effectiveness of drugs and  
devices in meta-analysis
The short answer to the question: ‘does 
anything work?’ is ‘no therapy has proven to be 
effective’, at least according to the Cochrane meta-
-analysis of randomized parallel and cross-over 
trials of drug and pacemaker therapy for NCS 
(Table 1) [4]. A second recent meta-analysis con-
firmed the Cochrane findings, this time including 
non-randomized as well as randomized studies 
(Table 1) [5]. Taking only randomized studies with 
placebo or non-active (that is placebo) device, only 
selective serotonin reuptake inhibitors (SSRIs) and 
midodrine (but not etilefrine) decrease syncope 
recurrence.
However, the totality of evidence for SSRIs 
derives from 2 studies (n = 131) and for midodrine 
4 studies (n = 136). Beta-blockers, tilt training, 
and pacing all failed to affect syncope recurrence 
in robustly designed trials, although many studies 
were arguably underpowered or projecting an 
ambitious relative risk reduction. Specifically in 
pacing, meta-analysis of 9 randomized trials reve-
aled reduced risk of syncope in unblinded studies 
and those comparing pacemaker algorithms, but 
not in double-blinded trials [6].
The meta-analyses highlight the limitations 
of current evidence and inefficacy of current the-
rapies. Effect size was markedly greater when 
comparing the intervention to standard treatment 
(usually non-pharmacological or other pharma-
cological therapy) as opposed to placebo or non-
-active device. Confidence intervals were wide 
even after aggregating studies, reflecting small 
patient numbers and variable treatment effect. All 
3 meta-analyses detected significant heteroge-
neity. Finally, only 2 outcomes were consistently 
reported: syncope recurrence and syncope during 
provocation.
Effectiveness and study design
Study size and design overwhelmingly influ-
ence apparent effect size [7]. The NCS literature 
is characterized by small to medium sized studies 
Table 1. Treatment effect size in randomized trials of drug and device therapy for neurocardiogenic 
syncope in the Cochrane Library meta-analysis.
Outcome Meta-analysis 
randomized  
(Cochrane) [4] 
Standard  
treatment 
Meta-analysis  
randomized  
(Cochrane) [4]
Placebo or non-active  
pacemaker
Meta-analysis  
randomized  
or non-randomized  
(Vyas et al.) [5]
Beta-blockers
Syncope recurrence 0.36 (0.21–0.62) 1.07 (0.80–1.44) 0.48 (0.22–1.04)
Provocation syncope 0.75 (0.58–0.97) 0.32 (0.14–0.73) parallel –
0.87 (0.31–2.43) cross
Alpha-adrenergic
Syncope recurrence – – 0.35 (0.04–2.88) etilefrine
0.12 (0.05–0.26) midodrine
Provocation syncope – 0.94 (0.59–1.48) etilefrine –
0.12 (0.04–0.36) midodrine
Selective serotonin  
reuptake inhibitors
Syncope recurrence – 0.39 (0.20–0.76) 0.28 (0.10–0.74) randomized
Provocation syncope – 0.75 (0.51–1.11) –
Tilt training
Syncope recurrence – – 0.30 (0.15–0.61)
0.47 (0.21–1.05) randomized
DDD pacemaker
Syncope recurrence 0.20 (0.10–0.40) 0.89 (0.58–1.38) non-active 0.45 (0.09–2.14) non-active
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with inadequate controls and conflicting results. 
Many factors have hindered the evolution of evi-
dence: (1) Early studies predated widespread adop-
tion of the multicenter randomized controlled trial; 
(2) Therapies are off-patent with limited industry 
support for trials; (3) The target population lacks 
a gold-standard diagnostic test.
The Cochrane assessment identified many 
sources of bias including randomization and 
sequence generation, allocation concealment, 
blinding, incomplete outcome data, and selective 
reporting. Small, non-randomized studies also 
increase susceptibility to publication bias. This 
is particularly true in conditions with infrequent 
outcomes, where a chance change in frequency 
of syncope may influence small studies. Possible 
bias was detected by funnel plot in the most recent 
meta-analysis [5].
Robust study design failed to support any 
therapy in NCS. The best beta-blocker evidence 
(or lack thereof) comes from the Prevention of 
Syncope Trial (POST), which randomized 208 pa - 
tients with recurrent syncope and positive tilt 
table test to receive metoprolol or placebo [3]. No 
difference was observed in recurrence of syncope, 
even when stratified by age and isoproterenol re-
sponse during tilt test. Subsequent pooled analysis 
with non-randomized patients found a significant 
interaction of beta-blockers with age, suggesting 
benefit after age 42, and potential harm in younger 
patients [8].
Likewise, the Vasovagal Syncope Inter - 
national Study (VASIS) demonstrated no benefit to 
etilefrine in a randomized, double blind, placebo- 
-controlled multicenter trial [9]. The second 
Vasovagal Pacemaker Study (VPS II) and vasovagal 
syncope and pacing trial (SYNPACE) contradicted 
the apparent efficacy of earlier non-blinded studies 
when patients received pacemakers with concealed 
randomization to active pacing or off [1, 2].
Effectiveness of non-pharmacological  
treatment (and the placebo effect)
Non-pharmacological interventions (educa-
tion, increasing fluid and salt, physical counter-
-pressure maneuvers) are considered first-line 
treatment in guidelines due to sound physiologic 
rationale, simple implementation, and the absen-
ce of harm, side effects or additional cost [10]. 
Counselling focuses on educating the patient and 
the family to understand the condition, emphasiz-
ing the benign prognosis and trigger avoidance. 
Hydration and liberalizing salt intake improves 
orthostatic tolerance to tilt testing in small acute 
or short-term studies, increasing plasma volume, 
cerebrovascular and peripheral vascular control 
[11, 12]. No long-term, controlled evidence exists 
for any conservative treatment.
However, syncope recurrence decreases over 
time in cohorts without additional intervention 
(syncope is self-limited for the majority) [13, 14]. 
In 100 patients with NCS, the median number of 
syncopal recurrences was significantly lower in the 
first year after vs. before non-pharmacological treat - 
ment (median 0 vs. 3; p < 0.001) [14]. A placebo 
effect, regression to the mean, and spontaneous 
improvement undoubtedly contribute. However, 
the principle precept of medical practice applies: 
first — do no harm. These low-risk lifestyle recom-
mendations are therefore favored, with diagnosis 
and reassurance the cornerstones of management 
despite lack of comparative evidence to support 
their use.
Physical counter-pressure maneuvers (PCM) 
involve isometric contractions of legs or arms or 
squats during the patient’s prodrome. Two initial 
studies demonstrated that arm tensing and leg 
crossing raised blood pressure 30% to 60% and 
postponed or prevented symptoms on tilt-table 
testing [15, 16]. The subsequent Physical Count-
erpressure Maneuvers Trial (PC Trial) randomized 
223 patients with NCS and prodromal symptoms to 
PCM or conventional therapy, blinding patients to 
randomization allocation. Despite a similar number 
of pre-syncopal episodes in each arm, fewer PCM 
patients progressed to syncope. The respective 
syncope recurrence rates were 31.6% vs. 50.9% 
over 14 months mean follow-up (RR 0.36; 95% 
CI 0.11–0.53) [17]. The intervention requires 
compliance, which in itself promotes a placebo 
effect. However, the nature of the intervention 
prevents double blind investigation. Moreover, 
the beneficial effect of training is inherent to the 
treatment and equally useful whether ‘placebo 
effect’ or otherwise.
Syncopal frequency profoundly improves in 
the control arms of almost every study compared 
to baseline. This ‘placebo effect’ has three drivers 
of pre-to-post change: (1) Random events and 
measurement/recall error contribute to inherent 
variability; (2) The condition improves either spon-
taneously or in response to previous interventions 
e.g. education or reassurance; (3) The intervention 
or placebo imposes an additional effect above the 
inherent variability and evolving disease state.
The magnitude of this placebo effect is signi-
ficant in NCS. For example, implanting a cardiac 
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monitor with no direct therapeutic efficacy redu-
ces events. In 25 patients with severe vasovagal 
syncope (mean of 6.9 ± 4.6 episodes per year), 
only 12 experienced any syncope over 17 months 
post implantable cardiac monitor (ICM) [18]. The 
placebo effect appears greater for devices than 
drugs. First, syncope recurrence is reduced more 
in the placebo arms of pacemaker studies than drug 
trials. Second, the apparent treatment effect of 
pacemakers is greater than drugs in non-controlled 
trials (i.e. larger placebo effect). Finally, pacing is 
far superior to beta-blocker in a direct comparison, 
suggesting greater placebo effect given the lack of 
proven efficacy for either strategy [19].
How is effectiveness defined?
When considering: “does anything work?”, 
‘work’ must be defined. From the patient perspec-
tive, patient relevant outcomes are defined as ‘how 
a patient feels, functions or survives’ [20]. These are 
divided into benefit outcomes and harm outcomes 
[21]. The former include ‘hard endpoints’ (death, 
hospitalization), symptoms and health-related 
quality-of-life (QOL). Since NCS does not affect 
survival, symptoms and QOL must be balanced 
against adverse effects. This balance involves 
weightings of complex multidimensional struc-
tures. Individual patients assign value differently 
to symptoms and domains of QOL. Both benefit 
and harm effects vary in magnitude depending 
on treatment, outcome assessed, time frame and 
population. For example, pacing in major registries 
conveys significant morbidity even in the short 
term. What improvement in QOL is worth trading 
for a lifetime risk of pacing complications, when not 
one of the NCS pacing trials reported any major 
injuries related to syncope?
No guideline or consensus document has 
specifically addressed how efficacy should be 
defined. Table 2 outlines potential outcomes. The 
Cochrane meta-analysis delineates a hierarchy of 
patient relevant outcomes: metrics of syncope are 
followed by QOL, incidence of physical trauma, 
and severity of side effects. Syncope induced by 
provocation occupies the final and least impactful 
position in the hierarchy.
Tilt testing has almost no value in assessing 
treatment efficacy [10]. Reproducibility varies up 
to 90% depending on the response [4]. Positive 
responses decrease with repeated testing irre-
spective of assigned treatment, with approximately 
50% of patients responding to placebo [22]. With 
respect to QOL, remarkably few studies in the 
Cochrane meta-analysis reported any measure: 
3 of 16 beta-blocker, 2 of 8 alpha-adrenergic agonist; 
1 of 2 SSRI, and 1 of 9 pacing studies [4]. Only 3 of 
these studies employed a validated questionnaire, 
the remainder consisting of self-reported well-
-being and scales without validation.
Table 2. Potential outcomes of interest when managing neurocardiogenic syncope.
Outcome Comments
Survival Death Not affected by neurocardiogenic syncope
Syncope recurrence Episodes per unit time
Proportion with recurrence
Time to recurrence
Optimal metric in relation to quality of life unknown
Association with quality of life poorly understood
Quality of life Disease specific questionnaire
Generic questionnaire
Disability/restriction
Trauma/injury
Standardized tools rarely used in trials to date
Treatment Adverse effects
Compliance, discontinuation
Placebo effect
Severity and time frame of assessment important
Placebo effect powerful and inherent to therapy
Healthcare utilization Hospitalization
Emergency Department visit
Clinic or medical contact
Patient and health system relevant outcomes
Interaction with quality of life merits investigation
Economic Cost-effectiveness Requires standardized measure of health utility
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How and why are patients impaired?
Patients with NCS report worse QOL and 
experience higher levels of anxiety, depression 
and somatization disorders than control popula-
tions [23, 24]. The level of impairment is similar 
to severe arthritis, pain, epilepsy and other chro-
nic disorders. In cohort studies both generic and 
disease specific questionnaires point to several key 
domains of impairment: fear, worry and embar-
rassment; depression and anxiety; activity impair-
ment including mobility, driving, employment, and 
exercise; interference with relationships [25–28].
However, although syncope burden and QOL 
exhibit a dose-response relationship, the correlation 
coefficient is weak and most apparent in more severe 
cases [14, 23, 26]. Given the complex pathophysio-
logy and precipitants, complete eradication of symp-
toms is unlikely in many patients. It is therefore 
likely that simply targeting reduction in syncope 
burden will have at best a modest effect on QOL.
Cognitive behavioral therapy addresses thou-
ghts, beliefs and somatic attention that sustain 
disability and distress. Syncope sufferers have 
many therapeutic targets: perceived likelihood of 
fainting, negative consequences, and lack of con-
trol; unfounded activity restriction, avoidance and 
protective behavior; vigilance of somatic signs lin-
ked with fainting and amplification by fear arousal. 
In a small retrospective observational series of 
9 patients, syncopal episodes and medical consulta-
tions significantly reduced following psychology 
intervention aiming to restructure maladaptive 
beliefs and somatic attention [29]. These prelimi-
nary findings merit further exploration in larger 
cohorts, but in some respects lack champions of 
the technique in the syncope realm.
Is guided therapy effective?
Lack of evidence from controlled clinical 
trials mandates reliance on personal experience 
and observations. Physician’s “gestalt” is difficult 
to quantify and patient selection may improve 
response in select cases despite trial evidence to 
the contrary. Choices are limited when treating 
a patient. Nevertheless, we equally recognize the 
numerous alternate explanations for anecdotal 
response: placebo or expectation effect, attrition 
and follow-up bias, observer and recall bias, the 
play of chance or regression to the mean.
Tailoring therapy to individual patient phy-
siology was for years the Rosetta Stone of NCS 
research, exemplified by the Vasovagal Syncope 
International Study (VASIS) classification based on 
tilt testing response [30]. Subsequent randomized 
trials selecting patients with specific character-
istics unequivocally refuted such approaches. 
How ever, the reliance on tilt testing to characterize 
phenotypes has arguably been the greatest inadver-
tent flaw in guided therapy strategies. Provocation 
induces a physiological response, not the actual 
event. Rhythm disturbance during provocation 
is common and correlates poorly with real-life 
spontaneous syncope [31, 32]. The sensitivity and 
specificity for events is accordingly low, preventing 
a homogeneous population being defined.
Beyond placebo effect, pacing can only be 
effective when syncope is secondary to asystole. 
Two studies, including the Second International 
Study on Syncope of Uncertain Etiology (ISSUE-2), 
examined reproducibility of electrocardiographic 
findings in NCS patients with an ICM and ≥ 2 syn-
copal episodes (n = 12 and n = 22) [18, 33]. The 
rhythm during first recurrence (abnormal or not) 
was almost identical in subsequent recurrences, 
although only a minority were actually attributable 
to bradyarrhythmia/asystole (n = 1/12 and n = 6/22).
Nevertheless, the findings suggest ICMs may 
overcome 2 key limitations of tilt testing: reproduci-
bility and association with spontaneous events. The 
International Study of Syncope of Uncertain Etio-
logy (ISSUE-3) trial tested this hypothesis, rando-
mizing 77 patients with purported neurally-mediated 
syncope and ICM documented asystole (mean 11 s) 
to dual chamber pacing with rate-drop response or 
sensing only [34]. Respectively, 25% vs. 57% of 
patients had syncope recurrence at 2 years, a 57% 
risk reduction (95% CI 4–81). Although promising, 
the many aforementioned caveats apply: patients 
were highly selected; risks outweighed benefits 
(5 pacing complications vs. no major adverse events 
secondary to syncope); high recurrence despite op-
timal treatment (25%), and QOL was not assessed.
There is emerging evidence that adenosine 
triphosphate (ATP) hypersensitivity may guide 
pacemaker selection in refractory cases. In IS-
SUE-2 and smaller cohort studies, a positive ATP 
test failed to predict syncopal recurrence and 
had no correlation with ICM documented rhythm 
during spontaneous syncope [18, 31]. However, 
the recent single-blinded ATP Multicenter Study 
randomized 80 elderly patients (mean age 75.9 ± 
± 7.7 years) with syncope of unknown origin and 
positive ATP test to active or backup pacing, with 
syncope recurred in 21% vs. 66%, respectively (HR 
0.25; 95% CI 0.12–0.56) [35]. This trial strongly 
supports the use of the test in patients in whom 
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pacing is contemplated, but uptake in practice and 
guidelines has been cautious. Differences in study 
populations and diagnostic criteria may partly ex-
plain the discrepancy with earlier cohort studies.
A final conundrum has emerged from subgroup 
analysis of ISSUE-3 [36]. In 136 NCS patients with 
implantable loop recorder (ILR) documented asy-
stole, asystolic response during baseline tilt test 
had no diagnostic utility in predicting recurrence 
or electrocardiogram pattern during episodes. 
However, pacing only prevented syncope recur-
rence in patients with a previous negative tilt test. 
Pacing was ineffective in those with positive tilt 
tests despite subsequent documented asystole, the 
recurrence rate being similar to untreated patients 
and presumably reflecting concurrent vasodepres-
sor response. This inverts previous indications 
for pacing and shifts tilt testing from a diagnostic 
to therapeutic guide. The challenge now becomes 
finding the optimal combination of ILR monitoring, 
tilt and ATP testing to accurately segregate the 
population most likely to benefit from pacing.
What are realistic goals?
The lifetime risk of syncope in the general popu-
lation exceeds 30%, with many experiencing recur-
rent symptoms [37]. For NCS, recurrence rates within 
1 year typically approach one third of patients, even 
with optimal treatment in the most robust studies 
(Table 3). Pre-syncope is even more common, with 
83% of patients in the PC trial and 96% in VPS II re-
porting symptoms [17]. Couple these outcomes with 
poorly understood mechanisms and confounding ortho-
static and autonomic syndromes, and the target ‘re-
sponse’ becomes even less certain. If we acknowledge 
the implausibility of widespread complete success, we 
must better understand how less frequent syncope and 
pre-syncope may become more acceptable to patients, 
in effect “debulking” the disease.
What is effective for the population  
and health system?
From a population perspective, guided therapy 
limits generalizability. In the major pacing trials 
< 5% of patients screened were eligible. Recruit-
ment rates in multicenter trials highlight the same 
challenge. For example, the PC-trial of counter-
pressure maneuvers included recurrent vasovagal 
syncope with prodromal symptoms [17]. In 
22 months, 223 patients were recruited in 15 centers 
(8.1 patients per center per year).
By contrast, ISSUE-3 mandated ≥ 3 s syncopal 
asystole or ≥ 6 s asymptomatic asystole [34]. In 
48 months, 77 patients were enrolled in 29 centers 
(0.7 patients per center per year). Obviously far 
fewer patients have recurrent NCS associated with 
significant asystole, limiting the population impact 
of the intervention.
From a health system or government per-
spective, a simple low-cost intervention with 
even mild symptomatic improvement is highly 
effective if medical contacts, Emergency Depart-
ment (ED) attendances and hospitalizations are 
reduced. The patients with refractory symptoms 
attending specialized services in the aforemen-
tioned trials represent the tip of the iceberg. 
For example, the crude cumulative rate of syn-
cope events in the ED is approximately 1/1,000 
person-years, 10/1,000 person-years in general 
practice, and 30/1,000 person-years in the gene-
ral population [38]. At the population level, ‘the-
rapies’ include patient and healthcare professio-
nal education, guidelines, screening programs, 
lifestyle interventions, referral pathways, and 
information systems. Although specialty multi-
disciplinary clinics manage a smaller population, 
those patients place a disproportionate burden 
on non-elective services and health system 
resources.
Table 3. Syncope and pre-syncope rates in treatment arms of randomized controlled trials.
Authors, years, trial Patients/ 
/Centers (n)
Intervention Follow-up Syncope  
recurrence
Pre-syncope
van Dijk et al., 2006 [17] PC Trial 223/15 Counterpressure 14 months 32% (31/98) 83% (81/98)
Duygu et al., 2008 [42] 82/1 Orthostatic 1 year 37% (15/41) –
Raviele et al., 1999 [9] VASIS 126/20 Etilefrine 262 days 24% (15/63) 41% (26/63)
Sheldon et al., 2006 [3] POST 208/14 Metoprolol 1 year 36% (38/107) –
Theodorakis et al., 2006 [41] 96/1 Fluoxetine 6 months 9% (3/32) 12% (4/32)
Connolly et al., 2003 [1] VPS II 100/15 Pacing 6 months 33% (16/48) 96% (46/48)
Brignole et al., 2012 [34] ISSUE-3 77/29 Pacing 2 years 25% –
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Direction for clinical services  
and research
Effective treatment of NCS requires a multi-
dimensional strategy addressing all sections 
of the population. The community burden and 
prognosis needs to be defined, along with simple 
cost-effective strategies for diagnosis, screening, 
and risk stratification. The impact of brief educa-
tional and behavioral interventions in primary care 
should be investigated. Linked data systems and 
registries will prove invaluable in understanding 
transitions between primary care, ED attendances 
and unplanned hospitalizations. Rapid access to 
records of previous investigations and diagnoses 
would assist practitioners in reassuring patients, 
avoid hospitalizations, and hopefully alleviate 
maladaptive fears and beliefs. Standardized diag-
nostic criteria and therapeutic guidelines are 
equally important.
Randomization, blinding, and placebo or in-
active comparators are essential in future studies to 
reduce bias. Optimal non-pharmacological therapy 
is equally important, to reduce confounding by 
simultaneous lifestyle change. All studies should 
measure symptom severity, generic and disease 
specific QOL. Generic instruments permit com-
parisons across populations and economic analysis 
(e.g. SF-36) [14, 39]. Disease-specific measures 
assess the impact on daily living and facilitate com-
parisons between studies in patients with the same 
disease (e.g. SFSQ and ISQL) [14, 27, 39]. Efforts 
should focus on understanding the mechanisms 
of psychological and social impairment through 
qualitative research. The applicability and cost-
-effectiveness of individual cognitive behavioral 
therapy, group therapy, and standardized educa-
tional material should be investigated.
Clearer definition of phenotypes and physio-
logy is required. Obtaining a symptom rhythm cor-
relation with burgeoning patch and ICM technology 
assists in defining normal as much as abnormal 
rhythm. Early vasoconstrictor studies examined 
patients with a vasodepressor provocation re-
sponse, many of whom suffer bradyarrhythmia 
during spontaneous episodes [31]. Excluding these 
patients may improve the overall effectiveness of 
vasoconstrictors.
Acknowledging methodological limitations, 
midodrine demonstrates therapeutic potential with 
a weighted mean relative risk reduction of 62% for 
syncope in 5 prospective controlled studies [40]. 
The Prevention Of Syncope Trial IV (POST IV) 
multicenter randomized controlled trial is currently 
comparing midodrine to placebo in patients with 
recurrent vasovagal syncope diagnosed according 
to the Calgary Syncope Symptom Score [40]. The 
SSRIs also merit revisiting, particularly in conjun-
ction with more detailed QOL and psychological 
assessment. The preliminary studies had insuf-
ficient sample size to demonstrate efficacy [41], 
but consistent direction and magnitude of effect 
in meta-analysis.
A lesson from hypertension clinic
The modern management of hypertension 
has shifted from maximal doses of a single agent 
to comprehensive lifestyle recommendations and 
multidrug strategies to address the many physio-
logic contributors to hypertension. NCS is in effect 
“Hypotension Clinic”, but even more challenging 
because events are paroxysmal. Thus, expecting to 
address recurrent NCS with a single drug interven-
tion is akin to the treatment of hypertension from 
30 years ago. Multiple elements of blood pressure 
generation, regulation and alteration are likely to 
be required to effectively manage a troublesome 
case. Despite a lack of compelling evidence, the 
authors advocate a multidimensional approach to 
this challenging problem that focuses on:
1. Increasing blood pressure reserve.
2. Recognizing triggers and responding promptly.
3. Minimizing pharmacologic interventions that 
focus on nuances of patients and their phy-
siology.
4. On-going enrollment in clinical trials to better 
define effective therapies.
Conclusions
Much priority has been assigned to better 
understanding the pathophysiology of NCS in 
order to match phenotypes and therapies. Aside 
from the limited efficacy to date, the complexity 
of personalized medicine adds many challenges 
including generalizability, cost-effectiveness, and 
implementation. A simpler approach is to deliver 
non-pharmacological interventions in the broadest 
sense to the broadest population. Exploring patient 
fears, misconceptions and behaviors may equally 
improve symptoms and morbidity. Finally, pharma-
cologic and device interventions should be used 
humbly and sparingly, with attempts to personalize 
therapies with “eyes wide open” regarding the 
weak evidence to support their use.
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